MaxCyte: Driving New Generation of Cell-Based Medicines
Hitachi Chemical Advanced Therapeutics Solutions Completes Technology Transfer to Enable Manufacturing of MaxCyte’s CARMA™ Cell Therapy for Clinical Use
MaxCyte to Present on Its CARMA™ Platform During Biotech Showcase™and Phacilitate: Leaders World/World Stem Cell Summit 2019
MaxCyte has committed itself to fostering workplace development, diversity, and inclusion (WDDI) at MaxCyte and across the biotechnology industry. We are dedicated to being at the forefront of efforts to develop a diverse and talented global workforce. To that end, we affirmatively support the following WDDI Principles adopted by the Biotechnology Innovation Organization (BIO), and pledge to do our part to foster diversity and inclusion among our employees, customers, and patients.
February 6, 2018
See BIO’s latest periodic updates on key issues facing the advancement of science and the ability of researchers and entrepreneurs to deliver the latest medical and biological breakthroughs to people who need them around the world.
July 26, 2017
Learn about the impact of biotechnology on patients and society, as well as the factors needed to keep the innovation engine running strong.
April 7, 2017x
Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter